VIDO’s COVID-19 vaccine receives Health Canada clinical trial approval
Dec 22, 2020 - The Vaccine and Infectious Disease Organization at the University of Saskatchewan has received a notice of authorization from Health Canada to initiate a Phase 1 clinical vaccine trial.
VIDO-InterVac on track to become ‘Canada’s centre for pandemic research’
Dec 11, 2020 - A major takeaway from the COVID-19 pandemic is that emerging diseases require rapid responses and Canada needs to be better prepared to respond to the next one, says University of Saskatchewan research centre leader Dr. Volker Gerdts.
New CT scanner gives USask’s VIDO-InterVac scientists a window on COVID-19 disease
Nov 6, 2020 - New imaging equipment to help understand COVID-19 infection will soon be coming to the VIDO-InterVac at the USask, thanks to a Canada Foundation for Innovation grant announced today by Prime Minister Justin Trudeau.
Extending the lifespan of N95 masks
Nov 3, 2020 - Researchers at the CLS and VIDO-InterVac are working together to better understand how decontamination procedures might affect the structure and potential reuse of N95 masks.
USask VIDO-InterVac expands international role to test antiviral compounds against COVID-19
Oct 13, 2020 - VIDO-InterVac at the University of Saskatchewan has been awarded a grant of almost $830,000 from the COVID-19 Therapeutics Accelerator to determine the effectiveness of several antiviral compounds against COVID-19.
Canadian universities partner to fight COVID-19 at USask’s VIDO-InterVac
Jul 22, 2020 - Infectious disease experts from Dalhousie University and University of Manitoba are joining the leading-edge research team at VIDO-InterVac on one-year secondments to collaboratively advance research and development against COVID-19.
CFI awards $77.5M to help major USask science facilities address COVID-19 and other global challenges
Jul 21, 2020 - Funding through the Canada Foundation for Innovation’s (CFI) Major Science Initiatives Fund ensures Canada’s large, national research facilities have the support needed to operate and stay on the leading edge of research.
Salmonella biofilm protein causes autoimmune responses—possible link with Alzheimer’s, Parkinson’s
Jul 9, 2020 - Scientists from VIDO-InterVac and Temple University in Philadelphia, Penn., have demonstrated that a salmonella biofilm protein can cause autoimmune responses and arthritis in animals.
Promising pre-clinical results for USask VIDO-InterVac COVID-19 vaccine
May 25, 2020 - A COVID-19 vaccine candidate developed by VIDO-InterVac has cleared another major milestone in moving towards human clinical trials: the novel vaccine has proven highly effective in ferrets, one of the commonly used animal models for COVID-19.
USask’s VIDO-InterVac and the National Research Council of Canada collaborate to advance development of vaccine against COVID-19
May 12, 2020 - VIDO-InterVac and NRC announced a collaboration to accelerate the development and production of a candidate COVID-19 antigen in mammalian cells.
ZYUS Collaborates with USask’s VIDO-InterVac to Develop a Plant-Based Vaccine for COVID-19
May 7, 2020 - ZYUS Life Sciences Inc. and VIDO-InterVac will collaborate to test plant produced antigens in a vaccine for COVID-19.
USask VIDO-InterVac awarded $23M for COVID-19 vaccine research
Apr 23, 2020 - VIDO-InterVac has been awarded $23 million to fast-track efforts to develop a COVID-19 vaccine, Prime Minister Justin Trudeau announced today.
Prime Minister announces new support for COVID-19 medical research and vaccine development
Apr 23, 2020 - $23 million announced to accelerate development of a vaccine against COVID-19. Funding will support pre-clinical testing and clinical trials of a potential COVID-19 vaccine, essential steps to ensuring that vaccines are effective and safe for human use.
SHA and VIDO-InterVac partner to help ensure supply of N95 respiratory masks
Apr 9, 2020 - The Saskatchewan Health Authority and VIDO-InterVac at the University of Saskatchewan are partnering on a way to safely decontaminate and reuse N95 respiratory masks that are normally thrown away after each use.
USask VIDO-InterVac and International Vaccine Institute collaborate on COVID-19 work
Mar 27, 2020 - IVI of South Korea, a world-renowned international organization founded by the United Nations Development Programme, is collaborating with VIDO-InterVac to better understand the virus causing COVID-19 and to develop vaccines and potential treatments.
Saskatchewan government invests $3.6M in USask COVID-19 vaccine research
Mar 25, 2020 - The Government of Saskatchewan has announced $3.6 million in new funding for VIDO-InterVac one of the world’s most advanced infectious disease labs and a leader in global efforts to find a COVID-19 vaccine.
New Money Aids Saskatchewan’s Search for Covid-19 Vaccine
Mar 25, 2020 - The Government of Saskatchewan and the Federal Government are committing $28 million to VIDO-InterVac to develop a vaccine for COVID-19.
PM announces $12M for new vaccine manufacturing at USask’s VIDO-InterVac, part of $23.3M for the lab to fight COVID-19 and other infectious disease threats
Mar 23, 2020 - As the COVID-19 outbreak continues to rapidly evolve, the federal government announced $23.3 million to support VIDO-InterVac, one of the largest and most advanced infectious disease research facilities in the world.
Canada’s plan to mobilize science to fight COVID-19
Mar 23, 2020 - Funding to strengthen COVID-19 vaccine development and expand bio-manufacturing capacity to support clinical trials
Saskatchewan Funds Coronavirus Vaccine Research
Mar 11, 2020 - Innovation Saskatchewan is providing researchers at the VIDO-InterVac with $200,000 to help find a vaccine for COVID-19.
VIDO-InterVac-led research team at USask awarded almost $1M to fight new coronavirus
Mar 6, 2020 - Researchers and collaborating scientists from across the country have been awarded almost $1 million over two years to develop animal models and test vaccine candidates for effectiveness and safety against the new coronavirus.
Canadian scientists first to test novel diagnostic tool for TB in bison
Feb 19, 2020 - To help protect Canada’s cattle and bison and maintain the country’s bovine tuberculosis-free status, scientists are conducting trials in bison of several diagnostic tools, including the Actiphage® blood test developed by PBD Biotech.
VIDO-InterVac approved to work on SARS-CoV-2
Jan 22, 2020 - Researchers have received permission from the Public Health Agency of Canada to start working on a vaccine for the coronavirus recently discovered in China, and they hope to have first candidates for testing in an animal model in six to eight weeks.
Increasing Canada’s Preparedness for African swine fever with the University of Saskatchewan’s VIDO-InterVac
Jan 8, 2020 - VIDO-InterVac is the first non-government facility in Canada to work with the ASF virus